Sunday 18 October 2026
Export XFOR’s income statement to Excel — free account
X4 Pharmaceuticals, Inc.
XFOR Healthcare Biotechnology
In the quarter to June 2026, revenue grew 346.3%, EPS grew 96.3%, free cash flow grew 13.8% and total debt rose 1.21%, each against the same quarter a year earlier.
2.59
0.05
−1.89%
Follow XFOR
X4 Pharmaceuticals, Inc. (XFOR) P/E ratio
X4 Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 10.8× (July 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
Low 0.0×
High 10.8×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ABEO Abeona Therapeutics Inc. compare | n/m |
| PRLD Prelude Therapeutics Incorporated compare | n/m |
| VNDA Vanda Pharmaceuticals Inc. compare | n/m |
| XFOR X4 Pharmaceuticals, Inc. | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| IKT Inhibikase Therapeutics, Inc. compare | n/m |
| RCKT Rocket Pharmaceuticals, Inc. compare | n/m |
| EYPT EyePoint, Inc. compare | n/m |
| PALI Palisade Bio, Inc. compare | 2.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)